SKA2

Across TCGA pan-cancer cohorts, SKA2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SKA2 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SKA2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SKA2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where SKA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.399	0.878	<.001	51	view →
LUAD	DFS	Median	All	0.334	0.896	.021	6	view →
HNSC	OS	Tertile	All	0.522	0.926	.008	6	view →
LSCC	DFS	Quartile	II,III,IV	0.862	0.506	.019	3	view →
GBM	DFS	Tertile	All	0.700	0.844	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SKA2–PDAC (DFS)

Open the PDAC breakdown →